Matches in Wikidata for { <http://www.wikidata.org/entity/Q65382216> ?p ?o ?g. }
Showing items 1 to 32 of
32
with 100 items per page.
- Q65382216 description "clinical trial" @default.
- Q65382216 description "ensayu clínicu" @default.
- Q65382216 description "klinisch onderzoek" @default.
- Q65382216 description "клінічне випробування" @default.
- Q65382216 description "կլինիկական փորձարկում" @default.
- Q65382216 name "A Phase 2 Study of Immunogenicity, Safety and Tolerability of CSL412 in Elderly Participants" @default.
- Q65382216 name "A Phase 2 Study of Immunogenicity, Safety and Tolerability of CSL412 in Elderly Participants" @default.
- Q65382216 type Item @default.
- Q65382216 label "A Phase 2 Study of Immunogenicity, Safety and Tolerability of CSL412 in Elderly Participants" @default.
- Q65382216 label "A Phase 2 Study of Immunogenicity, Safety and Tolerability of CSL412 in Elderly Participants" @default.
- Q65382216 prefLabel "A Phase 2 Study of Immunogenicity, Safety and Tolerability of CSL412 in Elderly Participants" @default.
- Q65382216 prefLabel "A Phase 2 Study of Immunogenicity, Safety and Tolerability of CSL412 in Elderly Participants" @default.
- Q65382216 P1132 Q65382216-DFA87784-E08B-4B59-8689-A90493DC7625 @default.
- Q65382216 P1476 Q65382216-D11EE270-5AD3-4A9E-A6CE-D26A9621E86F @default.
- Q65382216 P17 Q65382216-AFFB337D-4340-472D-BF20-100B99ABDC4A @default.
- Q65382216 P2899 Q65382216-53785C80-1755-4DBD-A3F8-3F622E6D80D6 @default.
- Q65382216 P3098 Q65382216-CA3C442C-FA70-47F6-837D-215E2A22054B @default.
- Q65382216 P31 Q65382216-FA96689C-5DB6-442B-BF09-52470D93ADEB @default.
- Q65382216 P580 Q65382216-CDE7C7B4-CFA0-4265-9424-482D7F06D9F0 @default.
- Q65382216 P582 Q65382216-6D1BB3D7-3037-4F01-A76D-DBE4AF21D942 @default.
- Q65382216 P6099 Q65382216-295994F6-A7AA-48A7-84E6-E70EE03E4408 @default.
- Q65382216 P8363 Q65382216-D0ACB8A7-24A1-4C91-9B9B-A76A9554EBF2 @default.
- Q65382216 P1132 "+612" @default.
- Q65382216 P1476 "A Phase II, Double-Blind, Randomised, Controlled, Multi-Centre Study to Evaluate the Immunogenicity, Safety and Tolerability of Three Formulations of CSL412 in Adults (≥ 18 to ≤ 45 Years) and Older Adults (≥ 60 Years)" @default.
- Q65382216 P17 Q145 @default.
- Q65382216 P2899 "+18" @default.
- Q65382216 P3098 "NCT00479648" @default.
- Q65382216 P31 Q30612 @default.
- Q65382216 P580 "2007-05-01T00:00:00Z" @default.
- Q65382216 P582 "2007-08-01T00:00:00Z" @default.
- Q65382216 P6099 Q42824440 @default.
- Q65382216 P8363 Q78089383 @default.